Dutch court axes Biogen’s MS patent, clearing way for generics

Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international litigation with mixed rulings | Generics still barred from selling products until early February.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

7 January 2026 As he hands over the baton, Bobby Mukherjee reflects on his time leading the Chartered Institute of Patent Attorneys—from progressing the soon-to-be-launched paid apprenticeship schemes to engaging with the UK body’s in-house members. Sarah Speight reports.

Europe

Edwards v Meril: Inside the UPC’s landmark medtech showdown

6 January 2026 As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party.

Europe

Key EU and UK regulatory changes to watch for in 2026

5 January 2026 A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.

More features

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

Bird & Bird targets Nordic life sciences growth with regulatory hire

Key EU and UK regulatory changes to watch for in 2026

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Dutch court axes Biogen’s MS patent, clearing way for generics

More on this story

Editor's picks

Editor's picks

More features